Patents by Inventor Seiji KAMIOKA

Seiji KAMIOKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190241583
    Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].
    Type: Application
    Filed: December 27, 2018
    Publication date: August 8, 2019
    Inventors: Hitoshi Ban, Seiji Kamioka, Shoukou Ri, Tomoyuki Furuta, Hiroyuki Kitano, Chiang Jia Li
  • Publication number: 20190084955
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
  • Patent number: 10183925
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 22, 2019
    Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
  • Publication number: 20180111914
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Application
    Filed: March 25, 2016
    Publication date: April 26, 2018
    Applicants: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Chiang Jia LI
  • Publication number: 20170015677
    Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].
    Type: Application
    Filed: March 30, 2015
    Publication date: January 19, 2017
    Applicant: Boston Biomedical, Inc.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Shoukou RI, Tomoyuki FURUTA, Hiroyuki KITANO, Chiang Jia Li